Release Date: 15-Jan-2025
Antibody drug conjugates (ADCs) hold potential as a future treatment option for pancreatic cancer, a notoriously aggressive and difficult-to-treat malignancy. Currently, no ADCs have been approved for pancreatic cancer, but ongoing research and clinical trials indicate that ADCs could eventually have a significant impact. Given the lack of effective treatments and the high mortality rate associated with pancreatic cancer, there is a strong need for innovative therapies. ADCs, which offer the possibility of selectively targeting and destroying cancer cells with minimal damage to surrounding healthy tissue, represent a promising approach.
Download Report: https://www.kuickresearch.com/report-cancer-drug-conjugates-market-size
More than 20 ADC candidates are currently in development for pancreatic cancer, though most are still in early-stage trials. Several are targeting specific proteins that are overexpressed in pancreatic tumors, including Claudin18.2 (CLDN18.2), TM4SF1, TROP2, nectin-4, and Fra. One of the leading candidates is IBI343, an ADC developed by Innovent Bio that targets CLDN18.2. IBI343 was granted FDA fast track designation in June 2024 for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC) that has relapsed or become refractory after one prior line of therapy. This fast-track designation underscores the potential of ADCs like IBI343 to address the unmet medical needs in pancreatic cancer.
Other ADCs in the pipeline include EO-3021, AZD0901, TORL-2-307, and SOT102, all of which also target CLDN18.2. These ADCs are being developed with the hope of overcoming the challenges associated with treating pancreatic cancer, including the tumor’s harsh microenvironment (TME) and poor drug delivery due to altered vascularization. ADCs like AGX101, which targets TM4SF1, LCB84 targeting TROP2, LY4101174 targeting nectin-4, and AMT-151 targeting Fra are among the many candidates under investigation.
Despite the promise shown by these early-stage candidates, the clinical translation of preclinical successes has yet to be fully realized in pancreatic cancer. Several barriers, including the unique and harsh TME, poor antigen-mediated ADC internalization, and limited drug delivery, pose significant challenges for ADC development in this area. Further research is needed to better understand the molecular mechanisms of both intrinsic and acquired resistance to ADCs in pancreatic cancer. This research could help refine ADC design, making them more effective against this particularly difficult cancer type.
The flexibility and versatility of ADCs as a therapeutic platform offer hope for overcoming these hurdles. Future work will likely focus on tailoring ADCs specifically for pancreatic cancer by improving tumor targeting, linker chemistries, and payload properties. With continued advances in these areas, ADCs could eventually play a key role in improving outcomes for pancreatic cancer patients, who currently have limited options.